Navigation Links
Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Date:7/2/2008

ements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the results of the subsequent stage for this trial will not be consistent with the results of the first stage. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
2. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
3. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
5. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
6. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
7. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
8. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
9. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning Benefits, ... Lockton Companies, announced the addition of Vice President ... join Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... relevant industry experience to the position.  Most recently, ... Sales at Diplomat Specialty Pharmacy, where she has ...
(Date:12/24/2014)...  Medical Science Liaisons play a large role in ... medical device industry and key stakeholders, the role of ... as the device industry relies on them to build ... benchmarking firm, Best Practices, LLC, one area where Medical ... by harnessing new technology to enable education. Online conferences ...
(Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... The Thompson Group of Companies announced today that ... a Hamilton Sundstrand Corporation business. AIT will be organized ... terms of the purchase were not disclosed. ... marketing of process analytical instruments including Analect FTIR, PIONIR ...
... Healthcare Diagnostics announces two new three-year agreements with Novation ... chemistry and microscopy systems, and for microbiology systems and ... VHA and University HealthSystem Consortium (UHC) member organizations and ... The members served by Novation have access to ...
Cached Medicine Technology:Thompson Group Acquires Hamilton Sundstrand's Applied Instrument Technologies 2Novation® Awards Siemens as Single Source for Urine Chemistry and Microbiology Systems and Tests 2
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) -- ... year will be allowed to donate blood in the United States, ... on donations from men who have sex with men. The ... a new draft guidance in early 2015 that would ultimately open ... is changing its policy based on data from other countries that ...
(Date:12/24/2014)... (HealthDay News) -- Adults who experienced childhood abuse ... headaches, suggests a study published online Dec. 24 ... maltreatment can have long-lasting effects, like associated medical ... author Dawn Buse, director of behavioral medicine at ... in a journal news release. "When managing ...
(Date:12/24/2014)... Steven Reinberg HealthDay ... New guidelines from the American Diabetes Association (ADA) call for ... with diabetes to help prevent heart disease. These new ... of Cardiology and American Heart Association, which also recommend giving ... heart disease, including people with diabetes. "We agree that ...
(Date:12/24/2014)... MA (PRWEB) December 24, 2014 Dr. ... Dentists from across the nation gathered with US Marines ... Dinner to raise funds for the Toys for Tots ... hundreds of thousands of new books and audio books ... go to underprivileged children this Christmas. It represents another ...
(Date:12/24/2014)... 24, 2014 Verde Pointe Dental Associates 2014 ... "Last years homemade Christmas sweater lit up, but this ... 2014 winner is Tandy Wilson for the second year in ... says Kirk Kimmerling DDS. "She took pictures of the entire ... sweater." , "Every year I enjoy stopping by ...
Breaking Medicine News(10 mins):Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2
... developing a kind of lab-on-a-chip which is a miniaturized, ... astronauts on long missions, who will need the ability ... allergies, anemia or deficiencies in the immune system. ... Space Biomedical Research Institute (NSBRI). ,Along with the ...
... and was later recommendation for all children 2 to 23 months ... pneumonia among young infants. //Studies suggest that the drop in ... due to immunization rather than the vaccine. ,This is ... showed a reduce in the infection rate. But in the present ...
... on the site of Birmingham's Queen Elizabeth Hospital is given a ... the West Midlands have already been announced//. It is funded by ... University Hospitals Birmingham NHS Trust said the trust's finances had been ... , The Treasury has also approved the scheme and said that ...
... watchdog warned the public about the poisonous nature of the apricot ... if consumed in larger quantities could be fatal. ... in death. A maximum of two bitter apricot kernels may be ... the seeds from shop shelves after it was found selling packs ...
... Although the International Monetary Fund on Tuesday gave an ... the dark clouds on the horizon// included worries about ... ,A global avian flu outbreak in humans could cause ... clearing, settlements, trading and communications, the IMF warned in ...
... is a foregone conclusion with no open choices. But does this ... a dignified// and peaceful death? The department of health recently ... of life care to the elderly. ,To research into ... in the sunset of their lives, often die a lonely death. ...
Cached Medicine News:Health News:Technology at its nano best: hand-held lab-on-a-chip for blood tests 2Health News:IMF considers Bird Flu to be a Dark Cloud 2
Cleveland Bone Cutter #5, 17cm, 6-3/4"...
Beuse Zygomatic Arch Awl with slightly curved tip....
Steroid-eluting, single-pass lead. CapSure VDD2 optimizes VDD therapy and offers easier handling, proven performance, and choice....
Steroid eluting pacemaker leads...
Medicine Products: